- This is the second patent ruling issued today from the Court in favor of Acadia
In the Order, the Court adopted Acadia’s interpretation of key disputed terms of the patent. Acadia believes that the Court’s interpretations affirm the strength of the patent. As a result of today’s order, a claims construction hearing (also referred to as a “Markman” hearing), which had been scheduled for
This was the second ruling issued today by the Court pertaining to Acadia’s patents covering NUPLAZID. Earlier today, in a separate litigation, the Court granted summary judgment to Acadia, confirming validity of Acadia’s ‘740 composition of matter patent.
“We are pleased to announce a second positive ruling today from the
The formulation patent that is the subject of today’s claims construction ruling is scheduled to expire in 2038. In addition, Acadia has a method of use patent on the 10mg tablet of NUPLAZID that runs to 2037 and a NUPLAZID composition of matter patent, which was the subject of today’s earlier ruling, that runs to 2030.
About NUPLAZID® (pimavanserin)
Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis by the
About
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements regarding the timing of future events. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization. For a discussion of these and other factors, please refer to Acadia’s annual report on Form 10-K for the year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20231213441201/en/
Media Contact:
Deb Kazenelson
(818) 395-3043
[email protected]
Investor Contact:
(858) 261-2872
[email protected]
(858) 261-2950
[email protected]
Source: